Get the Stockscreener App
2.09
0.97%
0.02
Phio Pharmaceuticals Corp stock is traded at $2.09, with a volume of 119.78K.
It is up +0.97% in the last 24 hours and down -17.06% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.07
Open:
$2.12
24h Volume:
119.78K
Relative Volume:
0.11
Market Cap:
$10.03M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.2563
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
-4.13%
1M Performance:
-17.06%
6M Performance:
+25.15%
1Y Performance:
-31.70%
1-Day Range:
$2.0031
$2.12
1-Week Range:
$1.91
$2.20
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.09 | 10.32M | 0 | -11.66M | -11.09M | -8.156 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the 7MM | DelveInsight - GlobeNewswire Inc.
How sentiment analysis helps forecast Phio Pharmaceuticals Corp.Trade Risk Assessment & Fast Gain Stock Tips - Newser
What analysts say about Phio Pharmaceuticals Corp. stock outlookSell Signal & Stock Market Timing Techniques - Newser
Is Phio Pharmaceuticals Corp. Stock Overbought or Oversold RSI Indicator AnalysisJuly 2025 PreEarnings & Stepwise Entry and Exit Trade Signals - Newser
Phio Pharmaceuticals Corp. Bounces Off Moving Average SupportMarket Growth Report & Community Consensus Trade Signals - beatles.ru
Using Bollinger Bands to evaluate Phio Pharmaceuticals Corp.2025 Technical Overview & Advanced Technical Analysis Signals - Newser
Identifying reversal signals in Phio Pharmaceuticals Corp.Market Performance Report & Verified Stock Trade Ideas - Newser
What is Phio Pharmaceuticals Corp. s P E ratio telling usJuly 2025 Recap & Real-Time Market Sentiment Alerts - 선데이타임즈
Combining machine learning predictions for Phio Pharmaceuticals Corp.July 2025 Selloffs & Real-Time Volume Analysis - Newser
Is now a turning point for Phio Pharmaceuticals Corp.Market Growth Report & Fast Moving Stock Trade Plans - Newser
HC Wainwright Reaffirms “Buy” Rating for Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Is Phio Pharmaceuticals Corp. stock poised for growthDollar Strength & Weekly Stock Performance Updates - Newser
Why Phio Pharmaceuticals Corp. stock attracts strong analyst attentionEarnings Overview Summary & Weekly Watchlist for Consistent Profits - Newser
Analyzing net buyer seller activity in Phio Pharmaceuticals Corp.2025 Earnings Impact & Short-Term Trading Opportunity Alerts - Newser
Phio Pharmaceuticals Corp.’s volatility index tracking explainedPortfolio Growth Summary & Long-Term Growth Portfolio Plans - Newser
Using Ichimoku Cloud for Phio Pharmaceuticals Corp. technicals2025 Biggest Moves & Trade Opportunity Analysis Reports - Newser
Is Phio Pharmaceuticals Corp. backed by strong institutional buyingJuly 2025 Macro Moves & Technical Pattern Based Signals - thegnnews.com
Order flow analysis tools used on Phio Pharmaceuticals Corp.Analyst Downgrade & Expert Curated Trade Ideas - Newser
Phio Pharmaceuticals Corp. Attempts Reversal From Key Support2025 Macro Impact & Reliable Price Action Trade Plans - classian.co.kr
Phio's Cancer Drug Shows Complete Response in 5 Patients as Cash Reserves Rise to $10.8M - Stock Titan
Chartists Watching For Breakout in Phio Pharmaceuticals Corp.2025 Price Targets & Entry Point Strategy Guides - 선데이타임즈
Phio Pharmaceuticals Corp. stock chart pattern explainedJuly 2025 Technicals & Real-Time Volume Analysis Alerts - Newser
Candlestick signals on Phio Pharmaceuticals Corp. stock todayMarket Trend Report & Risk Adjusted Buy/Sell Alerts - Newser
How Phio Pharmaceuticals Corp. stock performs during market volatilityMarket Risk Report & Real-Time Volume Analysis - Newser
Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Wednesday - Defense World
Can Phio Pharmaceuticals Corp. maintain its current growth rateWeekly Explosive Return Picks - thegnnews.com
What makes Phio Pharmaceuticals Corp. stock price move sharplyRapid Trade Forecast Based on Indicators - Newser
Phio Pharmaceuticals PHIO 2025Q2 Earnings Preview Downside Risk on Revenue Decline - AInvest
Best Value Stocks to Buy for May 28th - The Globe and Mail
Phio Pharmaceuticals Corp expected to post a loss of 36 cents a shareEarnings Preview - TradingView
When is the best time to exit Phio Pharmaceuticals Corp.Intraday Price Forecast Using Volume Models - Newser
Common Warts Clinical Trials, Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, Pipeline Analysis | Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Ph - Barchart.com
Is Phio Pharmaceuticals Corp. meeting your algorithmic filter criteriaFree Weekly Setup With 3x Return Potential - Newser
How strong is Phio Pharmaceuticals Corp. company’s balance sheetTriple returns potential - Jammu Links News
What are the latest earnings results for Phio Pharmaceuticals Corp.Unlock powerful stock screening techniques - Jammu Links News
Is Phio Pharmaceuticals Corp. stock overvalued or undervaluedAchieve breakthrough gains with smart trades - Jammu Links News
What analysts say about Phio Pharmaceuticals Corp. stockIdentify safe investments with exceptional yields - Jammu Links News
What are Phio Pharmaceuticals Corp. company’s key revenue driversBuild a winning investment portfolio - Jammu Links News
How volatile is Phio Pharmaceuticals Corp. stock compared to the marketFree Investment Community - Jammu Links News
How does Phio Pharmaceuticals Corp. generate profit in a changing economyFree Stock Selection - Jammu Links News
What catalysts could drive Phio Pharmaceuticals Corp. stock higher in 2025Achieve rapid growth with smart investments - jammulinksnews.com
How does Phio Pharmaceuticals Corp. compare to its industry peersFree Stock Market Knowledge Sharing - Jammu Links News
Should I hold or sell Phio Pharmaceuticals Corp. stock in 2025Triple-digit growth rates - Jammu Links News
What is the risk reward ratio of investing in Phio Pharmaceuticals Corp. stockPost Market Opportunities With High Returns - Jammu Links News
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):